Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Large Decrease in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHYGet Free Report) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 5,400 shares, a drop of 50.9% from the February 13th total of 11,000 shares. Based on an average trading volume of 9,900 shares, the days-to-cover ratio is currently 0.5 days.

Santen Pharmaceutical Price Performance

Shares of OTCMKTS SNPHY traded up $0.30 during midday trading on Friday, reaching $9.83. 3,213 shares of the stock were exchanged, compared to its average volume of 10,992. The firm has a 50-day simple moving average of $9.66 and a two-hundred day simple moving average of $10.86. Santen Pharmaceutical has a twelve month low of $8.65 and a twelve month high of $13.00.

About Santen Pharmaceutical

(Get Free Report)

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.

Featured Stories

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.